Insulin suspension isophane biosimilar - Sedico

Drug Profile

Insulin suspension isophane biosimilar - Sedico

Alternative Names: Insulin Hbio NPH; Recombinant human Insulin with Protamine sulphate - Sedico

Latest Information Update: 17 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sedico
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase antizyme stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 26 Feb 2014 Launched for Type-1 diabetes mellitus (in children and adolescents) in Egypt (SC)
  • 26 Feb 2014 Launched for Type-1 diabetes mellitus in Egypt (SC)
  • 26 Feb 2014 Launched for Type-2 diabetes mellitus (combination therapy) in Egypt (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top